MA27023A1 - Formes cristallines d'azithromycine - Google Patents

Formes cristallines d'azithromycine

Info

Publication number: MA27023A1
Authority: MA; Morocco
Prior art keywords: azithromycin; crystalline forms; crystalline; forms
Prior art date: 2001-05-22

Application number

MA27397A

Other languages

English (en)

Inventor

Jane Li Zheng

Vincent Trask Andrew

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-22

Filing date

2003-11-14

Publication date

2004-12-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27404135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27023(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-11-14 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-12-20 Publication of MA27023A1 publication Critical patent/MA27023A1/fr

Links

MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title 1
229960004099 azithromycin Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

MA27397A 2001-05-22 2003-11-14 Formes cristallines d'azithromycine MA27023A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US29256501P	2001-05-22	2001-05-22
US29774101P	2001-06-12	2001-06-12
US34304101P	2001-12-21	2001-12-21

Publications (1)

Publication Number	Publication Date
MA27023A1 true MA27023A1 (fr)	2004-12-20

Family

ID=27404135

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA27397A MA27023A1 (fr)	2001-05-22	2003-11-14	Formes cristallines d'azithromycine

Country Status (35)

Country	Link
US (10)	US6977243B2 (fr)
EP (1)	EP1390377B1 (fr)
JP (3)	JP2004530703A (fr)
KR (1)	KR100574153B1 (fr)
AP (1)	AP2003002906A0 (fr)
AR (1)	AR036022A1 (fr)
AT (2)	ATE404575T1 (fr)
AU (1)	AU2002256846B2 (fr)
BG (1)	BG108370A (fr)
BR (1)	BR0209918A (fr)
CA (1)	CA2391659C (fr)
CR (1)	CR7159A (fr)
CZ (1)	CZ20033154A3 (fr)
DE (2)	DE60228345D1 (fr)
DK (1)	DK1390377T3 (fr)
EA (2)	EA007618B1 (fr)
EE (1)	EE200300575A (fr)
ES (2)	ES2310886T3 (fr)
GE (1)	GEP20084399B (fr)
HU (1)	HUP0400446A2 (fr)
IL (1)	IL158591A0 (fr)
IS (1)	IS7007A (fr)
MA (1)	MA27023A1 (fr)
MX (1)	MXPA03010028A (fr)
MY (1)	MY129319A (fr)
NO (2)	NO321894B1 (fr)
NZ (2)	NZ539801A (fr)
PA (1)	PA8545701A1 (fr)
PE (1)	PE20021064A1 (fr)
PL (1)	PL367091A1 (fr)
PT (1)	PT1390377E (fr)
SK (1)	SK14402003A3 (fr)
TN (1)	TNSN03121A1 (fr)
WO (1)	WO2002094843A1 (fr)
YU (1)	YU91603A (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20020231A2 (en)	2002-03-18	2003-12-31	Pliva D D	ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
AU768219B2 (en) *	1998-11-30	2003-12-04	Teva Pharmaceutical Industries Ltd.	Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
WO2002015842A2 (fr) *	2000-08-23	2002-02-28	Wockhardt Limited	Procede de preparation d'azithromycine anhydre
KR100431431B1 (ko) *	2001-04-25	2004-05-14	한미약품 주식회사	아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
DK1390377T3 (da) *	2001-05-22	2006-06-19	Pfizer Prod Inc	Ny krystalform af azithromycin
ITMI20011762A1 (it)	2001-08-10	2003-02-10	Cosmo Spa	Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
PL371259A1 (pl) *	2001-12-21	2005-06-13	Pfizer Products Inc.	Bezpośrednio sprasowywalne preparaty azytromycyny
AU2002353316A1 (en) *	2001-12-21	2003-07-09	Pfizer Products Inc.	Methods for wet granulating azithromycin
BR0307331A (pt)	2002-02-01	2004-12-07	Pfizer Prod Inc	Formulações granuladas a seco de azitromicina
HRP20020614A2 (en)	2002-07-22	2004-06-30	PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o.	Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
CA2422972A1 (fr) *	2003-03-21	2004-09-21	Apotex Inc.	Isopropanolate d'azithromycine et methode de production connexe
US20050013835A1 (en) *	2003-07-15	2005-01-20	Pfizer Inc.	Stable non-dihydrate azithromycin oral suspensions
EP1878432A1 (fr) *	2003-07-24	2008-01-16	Pliva - Research and Development Ltd.	Azithromycine à dissolution rapide pour dose unique
EP1648473B1 (fr)	2003-07-24	2009-01-28	PLIVA HRVATSKA d.o.o.	Dose unique a dissolution rapide d'azithromycine
CA2678125C (fr) *	2003-11-17	2014-10-14	Merck Eprova Ag	Formes cristallines de dihydrochlorure de (6r)-l-erythro-tetrahydrobiopterine
US7943585B2 (en)	2003-12-22	2011-05-17	Sandoz, Inc.	Extended release antibiotic composition
US7468428B2 (en)	2004-03-17	2008-12-23	App Pharmaceuticals, Llc	Lyophilized azithromycin formulation
US20060116336A1 (en) *	2004-03-17	2006-06-01	American Pharmaceutical Partners, Inc.	Lyophilized azithromycin formulation
US20050250714A1 (en) *	2004-05-06	2005-11-10	Lin Kangwen L	Crystalline forms of 9-(S)-erythromycylamine
JP2008501657A (ja) *	2004-06-02	2008-01-24	サンド・アクチエンゲゼルシヤフト	結晶形態のメロペネム中間体
US7683162B2 (en)	2004-08-30	2010-03-23	Taro Pharmaceutical Industries Limited	Process of preparing a crystalline azithromycin monohydrate
US8495244B2 (en) *	2005-06-29	2013-07-23	Jumpstart Wireless Corporation	System and method for dynamic automatic communication path selection, distributed device synchronization and task delegation
US7750153B2 (en) *	2005-07-05	2010-07-06	Hetero Drugs Limited	Process for the preparation of didanosine using novel intermediates
EP1904510A1 (fr) *	2005-07-14	2008-04-02	Pfizer Products Incorporated	Procede de formation de particules d'azithromycine amorphe
CN101287706A (zh) *	2005-09-21	2008-10-15	尼科梅德有限责任公司	作为组蛋白脱乙酰基酶抑制剂的磺酰基吡咯盐酸盐
US7728129B2 (en) *	2005-10-31	2010-06-01	Janssen Pharmaceutica Nv	Processes for the preparation of piperazinyl and diazapanyl benzamide derivatives
US8558765B2 (en) *	2005-11-07	2013-10-15	Global Oled Technology Llc	Method and apparatus for uniformity and brightness correction in an electroluminescent display
AU2007260356B2 (en) *	2006-06-16	2013-01-24	H. Lundbeck A/S	Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
US7919598B2 (en) *	2006-06-28	2011-04-05	Bristol-Myers Squibb Company	Crystal structures of SGLT2 inhibitors and processes for preparing same
NZ598071A (en) *	2006-10-27	2013-08-30	Signal Pharm Llc	Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
CA2570949A1 (fr) *	2006-12-12	2008-06-12	Apotex Pharmachem Inc.	Solvate d'ibandronate sodique et de propyleneglycol et methodes de preparation connexes
US7834195B2 (en) *	2007-01-24	2010-11-16	Apotex Pharmachem Inc.	Atorvastatin calcium propylene glycol solvates
ITMI20071616A1 (it)	2007-08-03	2009-02-04	Cosmo Spa	Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
US7919676B2 (en)	2007-08-03	2011-04-05	Pioneer Hi-Bred International, Inc.	Msca1 nucleotide sequences impacting plant male fertility and method of using same
EP2085397A1 (fr) *	2008-01-21	2009-08-05	Esteve Quimica, S.A.	Forme cristalline d'abacavir
US7935817B2 (en) *	2008-03-31	2011-05-03	Apotex Pharmachem Inc.	Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) *	2008-04-15	2010-06-09	Basilea Pharmaceutica Ag	Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) *	2008-07-15	2012-01-17	Genesen Labs	Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
US8216363B2 (en) *	2008-10-27	2012-07-10	Illinois Institute Of Technology	Continuous antisolvent crystallization process and system using plug flow reactors
US20100158821A1 (en) *	2008-12-22	2010-06-24	Eastman Chemical Company	Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
CA2754604A1 (fr)	2009-03-13	2010-09-16	Da Volterra	Compositions et procedes d'elimination de bacteries gram negatives
US8106111B2 (en)	2009-05-15	2012-01-31	Eastman Chemical Company	Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
PT2544679T (pt)	2010-03-12	2019-07-11	Omeros Corp	Inibidores de pde-10 e composições e métodos relacionados
JP2013536859A (ja) *	2010-09-01	2013-09-26	アリーナファーマシューティカルズ，インコーポレイテッド	５−ｈｔ２ｃアゴニストの非吸湿性塩
JP2014530805A (ja) *	2011-09-30	2014-11-20	スンシネルアケプハルマカンパニーリミテッド	アジルサルタンの結晶形並びにその製造及び使用
WO2013088274A1 (fr)	2011-12-14	2013-06-20	Wockhardt Limited	Composition d'azithromycine amorphe anhydre dépourvue de dihydrate d'azithromycine
NZ630803A (en) *	2014-04-28	2016-03-31	Omeros Corp	Optically active pde10 inhibitor
NZ716494A (en)	2014-04-28	2017-07-28	Omeros Corp	Processes and intermediates for the preparation of a pde10 inhibitor
US9879002B2 (en)	2015-04-24	2018-01-30	Omeros Corporation	PDE10 inhibitors and related compositions and methods
EP3108879A1 (fr)	2015-06-25	2016-12-28	Cassiopea S.p.A.	Formulation à concentration élevée
US9920045B2 (en)	2015-11-04	2018-03-20	Omeros Corporation	Solid state forms of a PDE10 inhibitor
IL326637A (en) *	2017-09-07	2026-04-01	Atnx Spv Llc	Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
CN111303230B (zh) *	2020-03-09	2021-07-13	中国食品药品检定研究院	一种黄体酮共晶物及其制备方法和用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI7910768A8 (en) *	1979-04-02	1996-06-30	Pliva Pharm & Chem Works	Process for pripering 11-aza-4-0-cladinosyl-6-0-desosaminyl-15-ethyl- 7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl- oxacyclopentadecane-2-one and their derivatives
SI8110592A8 (en) *	1981-03-06	1996-06-30	Pliva Pharm & Chem Works	Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) *	1982-07-19	1984-10-02	Pfizer Inc.	N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4465674A (en) *	1983-09-06	1984-08-14	Pfizer Inc.	Azahomoerythromycin D derivative and intermediates therefor
RO107257B1 (ro) *	1987-07-09	1993-10-30	Pfizer	Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
WO1989002271A1 (fr) *	1987-09-10	1989-03-23	Pfizer	Azithromycine et derives utilises comme agents anti-protozoaires
US4983531A (en) *	1990-02-12	1991-01-08	Motorola, Inc.	Method of fabricating a single polysilicon bipolar transistor which is compatible with a method of fabricating CMOS transistors
CN1093370A (zh) *	1993-12-10	1994-10-12	北京市集才药物研究所	一种新的阿齐红霉素结晶及其制备方法
CN1034734C (zh)	1993-12-10	1997-04-30	北京市集才药物研究所	一种新的阿齐红霉素结晶及其制备方法
US5605889A (en) *	1994-04-29	1997-02-25	Pfizer Inc.	Method of administering azithromycin
CA2261732C (fr) *	1996-07-29	2001-07-24	Abbott Laboratories	Preparation de la forme cristalline ii de la clarithromycine
CN1161971A (zh)	1997-01-03	1997-10-15	石家庄制药集团有限公司	一种阿齐霉素结晶及其制备方法
PT102130A (pt)	1998-03-13	1999-09-30	Hovione Sociedade Quimica S A	Processo de preparacao de dihidrato de azitromicina
TW546302B (en) *	1998-05-08	2003-08-11	Biochemie Sa	Improvements in macrolide production
US6245903B1 (en) *	1998-08-21	2001-06-12	Apotex, Inc.	Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
KR100377159B1 (ko) *	1998-09-09	2003-08-19	한미약품공업 주식회사	잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
AU768219B2 (en) *	1998-11-30	2003-12-04	Teva Pharmaceutical Industries Ltd.	Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
ES2267549T3 (es) *	1999-06-29	2007-03-16	Sandoz Ag	Procedimiento para la produccion de azitromicina.
ES2177373B1 (es)	1999-11-26	2003-11-01	Astur Pharma Sa	Preparacion de azitromicina en su forma no cristalina
CA2396426A1 (fr)	2000-01-04	2001-07-12	Teva Pharmaceutical Industries Ltd.	Procede de preparation d'azithromycine dihydratee
ES2162764B1 (es)	2000-05-17	2003-04-01	Ercros Ind Sa	Forma polimorfica del dihidrato de azitromicina, y su procedimiento deobtencion.
WO2002007736A1 (fr)	2000-07-24	2002-01-31	Cadila Pharmaceuticals Limited	Fabrication d'une composition pharmaceutique liquide limpide d'azithromycine
ES2260047T3 (es) *	2000-07-25	2006-11-01	Laboratorio Silanes, S.A. De C.V.	Proceso de etapa unica para la preparacion de 7,16-deoxi-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihidroxi-6-etil-3,5,9,11,13,15-hexametilbiciclo(11.2.1)hexadeca-1(2)-en-ona y obtencion de una forma nueva de 9-deoxo-9a-metil-9a-homoeritromicina a.
ITBO20000471A1 (it)	2000-07-31	2002-01-31	Vieri Ridolfi	Dispositivo di supporto per prodotti da fumo particolarmente sigarette .
ES2172417B1 (es)	2000-07-31	2003-09-16	Sint Quimica Sa	Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden.
WO2002009640A2 (fr)	2000-08-01	2002-02-07	Shiva Prasad Singh	Élaboration d'azithromycine anhydre
WO2002015842A2 (fr)	2000-08-23	2002-02-28	Wockhardt Limited	Procede de preparation d'azithromycine anhydre
EE05200B1 (et)	2000-11-27	2009-08-17	Biochemie S.A.	Asitromtsiin monohdraadina, selle valmistamismeetod ja selle kasutamine ravimkoostises
IN190080B (fr)	2001-01-29	2003-06-07	Alembic Ltd
KR100431431B1 (ko)	2001-04-25	2004-05-14	한미약품 주식회사	아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
US6861413B2 (en) *	2001-05-22	2005-03-01	Pfizer Inc.	Stable non-dihydrate azithromycin oral suspensions
DK1390377T3 (da) *	2001-05-22	2006-06-19	Pfizer Prod Inc	Ny krystalform af azithromycin
EP1446010B1 (fr)	2001-10-18	2009-04-15	Teva Pharmaceutical Industries Ltd.	Compositions d'azithromycine stabilisees

2002
- 2002-05-01 DK DK02726369T patent/DK1390377T3/da active
- 2002-05-01 HU HU0400446A patent/HUP0400446A2/hu unknown
- 2002-05-01 ES ES06110765T patent/ES2310886T3/es not_active Expired - Lifetime
- 2002-05-01 PT PT02726369T patent/PT1390377E/pt unknown
- 2002-05-01 AP APAP/P/2003/002906A patent/AP2003002906A0/en unknown
- 2002-05-01 YU YU91603A patent/YU91603A/sh unknown
- 2002-05-01 NZ NZ539801A patent/NZ539801A/en unknown
- 2002-05-01 BR BR0209918-7A patent/BR0209918A/pt not_active IP Right Cessation
- 2002-05-01 JP JP2002591516A patent/JP2004530703A/ja not_active Withdrawn
- 2002-05-01 WO PCT/IB2002/001570 patent/WO2002094843A1/fr not_active Ceased
- 2002-05-01 AU AU2002256846A patent/AU2002256846B2/en not_active Ceased
- 2002-05-01 IL IL15859102A patent/IL158591A0/xx unknown
- 2002-05-01 MX MXPA03010028A patent/MXPA03010028A/es active IP Right Grant
- 2002-05-01 CA CA002391659A patent/CA2391659C/fr not_active Expired - Fee Related
- 2002-05-01 EA EA200301115A patent/EA007618B1/ru not_active IP Right Cessation
- 2002-05-01 DE DE60228345T patent/DE60228345D1/de not_active Expired - Lifetime
- 2002-05-01 EP EP02726369A patent/EP1390377B1/fr not_active Revoked
- 2002-05-01 PL PL02367091A patent/PL367091A1/xx not_active Application Discontinuation
- 2002-05-01 CZ CZ20033154A patent/CZ20033154A3/cs unknown
- 2002-05-01 NZ NZ529118A patent/NZ529118A/en unknown
- 2002-05-01 DE DE60209704T patent/DE60209704T2/de not_active Revoked
- 2002-05-01 GE GEAP20027185A patent/GEP20084399B/en unknown
- 2002-05-01 KR KR1020037015125A patent/KR100574153B1/ko not_active Expired - Fee Related
- 2002-05-01 EE EEP200300575A patent/EE200300575A/xx unknown
- 2002-05-01 EA EA200500630A patent/EA009611B1/ru not_active IP Right Cessation
- 2002-05-01 AT AT06110765T patent/ATE404575T1/de not_active IP Right Cessation
- 2002-05-01 AT AT02726369T patent/ATE319730T1/de not_active IP Right Cessation
- 2002-05-01 ES ES02726369T patent/ES2258142T3/es not_active Expired - Lifetime
- 2002-05-01 SK SK1440-2003A patent/SK14402003A3/sk unknown
- 2002-05-21 PE PE2002000431A patent/PE20021064A1/es not_active Application Discontinuation
- 2002-05-21 MY MYPI20021870A patent/MY129319A/en unknown
- 2002-05-21 US US10/152,106 patent/US6977243B2/en not_active Expired - Fee Related
- 2002-05-21 AR ARP020101875A patent/AR036022A1/es unknown
- 2002-05-22 PA PA20028545701A patent/PA8545701A1/es unknown
2003
- 2003-07-08 TN TNPCT/IB2002/001570A patent/TNSN03121A1/fr unknown
- 2003-08-27 US US10/650,253 patent/US7282486B2/en not_active Expired - Fee Related
- 2003-08-27 US US10/650,252 patent/US7307156B2/en not_active Expired - Fee Related
- 2003-08-27 US US10/650,254 patent/US20040138149A1/en not_active Abandoned
- 2003-08-28 US US10/652,962 patent/US20040043945A1/en not_active Abandoned
- 2003-08-28 US US10/652,655 patent/US7309782B2/en not_active Expired - Fee Related
- 2003-08-28 US US10/652,933 patent/US20050192234A1/en not_active Abandoned
- 2003-10-30 IS IS7007A patent/IS7007A/is unknown
- 2003-11-14 MA MA27397A patent/MA27023A1/fr unknown
- 2003-11-18 BG BG108370A patent/BG108370A/bg unknown
- 2003-11-20 CR CR7159A patent/CR7159A/es not_active Application Discontinuation
- 2003-11-21 NO NO20035177A patent/NO321894B1/no unknown
2005
- 2005-05-06 US US11/123,703 patent/US7081525B2/en not_active Expired - Fee Related
- 2005-05-06 US US11/123,542 patent/US7105179B2/en not_active Expired - Fee Related
- 2005-05-06 US US11/123,770 patent/US7053192B2/en not_active Expired - Fee Related
2006
- 2006-03-03 NO NO20061049A patent/NO20061049L/no unknown
- 2006-03-07 JP JP2006061758A patent/JP4584162B2/ja not_active Expired - Fee Related
2007
- 2007-02-09 JP JP2007030654A patent/JP2007161726A/ja active Pending

Also Published As

Publication number	Publication date
CR7159A (es)	2004-02-23
NO20035177D0 (no)	2003-11-21
KR100574153B1 (ko)	2006-04-25
BG108370A (bg)	2004-11-30
US6977243B2 (en)	2005-12-20
WO2002094843A1 (fr)	2002-11-28
EP1390377A1 (fr)	2004-02-25
DE60209704T2 (de)	2006-11-16
CA2391659A1 (fr)	2002-11-22
US7053192B2 (en)	2006-05-30
NZ529118A (en)	2005-10-28
DE60209704D1 (de)	2006-05-04
MXPA03010028A (es)	2004-02-12
US7282486B2 (en)	2007-10-16
EA200301115A1 (ru)	2004-04-29
NO321894B1 (no)	2006-07-17
JP2006152002A (ja)	2006-06-15
US20040043944A1 (en)	2004-03-04
AR036022A1 (es)	2004-08-04
ATE404575T1 (de)	2008-08-15
ATE319730T1 (de)	2006-03-15
EE200300575A (et)	2004-04-15
EA007618B1 (ru)	2006-12-29
GEP20084399B (en)	2008-06-10
US20040082527A1 (en)	2004-04-29
JP2004530703A (ja)	2004-10-07
HUP0400446A2 (hu)	2004-09-28
NZ539801A (en)	2006-10-27
AU2002256846B2 (en)	2007-04-05
US7105179B2 (en)	2006-09-12
US20050090459A1 (en)	2005-04-28
CA2391659C (fr)	2006-05-30
CZ20033154A3 (en)	2004-04-14
ES2310886T3 (es)	2009-01-16
KR20040014525A (ko)	2004-02-14
JP2007161726A (ja)	2007-06-28
PL367091A1 (en)	2005-02-21
AP2003002906A0 (en)	2003-12-31
BR0209918A (pt)	2004-03-30
US7307156B2 (en)	2007-12-11
EP1390377B1 (fr)	2006-03-08
SK14402003A3 (sk)	2004-06-08
US20040043945A1 (en)	2004-03-04
IL158591A0 (en)	2004-05-12
NO20061049L (no)	2003-05-12
IS7007A (is)	2003-10-30
PA8545701A1 (es)	2003-09-05
US20050192234A1 (en)	2005-09-01
PE20021064A1 (es)	2002-11-21
EA200500630A1 (ru)	2006-02-24
MY129319A (en)	2007-03-30
EA009611B1 (ru)	2008-02-28
TNSN03121A1 (en)	2005-12-23
DE60228345D1 (de)	2008-09-25
DK1390377T3 (da)	2006-06-19
US20050256062A1 (en)	2005-11-17
PT1390377E (pt)	2006-06-30
US20030162730A1 (en)	2003-08-28
US20040138149A1 (en)	2004-07-15
US20050245469A1 (en)	2005-11-03
US7309782B2 (en)	2007-12-18
JP4584162B2 (ja)	2010-11-17
ES2258142T3 (es)	2006-08-16
YU91603A (sh)	2006-08-17
US7081525B2 (en)	2006-07-25
US20050256063A1 (en)	2005-11-17

Publication	Publication Date	Title
MA27023A1 (fr)	2004-12-20	Formes cristallines d'azithromycine
FR20C1039I2 (fr)	2021-08-13	Derives de l'uk-2a
MA27126A1 (fr)	2005-01-03	3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES
NO20043110L (no)	2004-07-20	Direkte komprimerbare formuleringer av azitromycin
PT1169314E (pt)	2002-11-29	Base cristalina de citalopram
EP1442038A4 (fr)	2005-01-05	Formes cristallines d'antibiotiques a base de carbapeneme et procedes de preparation
DK1451192T3 (da)	2011-04-04	Ny krystallinsk forbindelse
EE200100135A (et)	2002-06-17	EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid
PT1119430E (pt)	2004-03-31	Fresa
PT1250321E (pt)	2006-09-29	Composicao de gliburida
PT1100326E (pt)	2003-08-29	Microcapsulas de libertacao activada por bases
MA26845A1 (fr)	2004-12-20	Forme cristalline de 4-carboxyamino-2-ethyl-1,2,3,4-
NO20020030L (no)	2002-03-05	Krystallinske 1-metylkarbapenemforbindelser
EP1418949A4 (fr)	2009-03-04	Inhibiteur de methylation d'adn
FR2824092B1 (fr)	2004-04-09	Ensemble d'elements de construction
PT1322592E (pt)	2004-12-31	Derivados substituidos de 1-aminobutan-3-ol
MA27240A1 (fr)	2005-03-01	Derives d'imidazoquinoleine
AR028070A1 (es)	2003-04-23	Sintesis de compuestos de ciclohexendimetanol o ciclohexandimetanol
IS5821A (is)	2001-01-23	Kristalluð form af ósanetant
ITBO20010485A0 (it)	2001-07-27	Unita' di ventilazione
PT1175417E (pt)	2004-04-30	Compostos substituidos de benzolactamas
NO20030419D0 (no)	2003-01-27	16<alfa>-metyl- eller etyl-substituerte estrogener
FI20015039L (fi)	2003-05-23	Tilaajatunnuksen siirrettävyys
EP1453813A4 (fr)	2005-02-09	PURIFICATION AMELIOREE DE 4, 4 (5 )-DI- i T /i -BUTYLCY CLOHEXANO-18-COURONNE-6
ITMI991721A0 (it)	1999-07-30	Metodo di cristallizzazione di sorbitolo e sorbitolo cristallizzato co si' ottenuto